These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 9519012

  • 1. PPIs vs H2RAs for erosive reflux esophagitis.
    King VJ.
    J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
    [No Abstract] [Full Text] [Related]

  • 2. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA, Kuppermann M, Richter JE.
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [Abstract] [Full Text] [Related]

  • 3. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y, Oyasu K, Wakamatsu T, Sumitomo Y, Kiyota K, Inokuchi H, Kawai K.
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [Abstract] [Full Text] [Related]

  • 4. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
    Habu Y, Maeda K, Kusuda T, Yoshino T, Shio S, Yamazaki M, Hayakumo T, Hayashi K, Watanabe Y, Kawai K.
    J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
    Ofman JJ, Yamashita BD, Siddique RM, Larson LR, Willian MK.
    Am J Manag Care; 2000 Aug; 6(8):905-16. PubMed ID: 11186502
    [Abstract] [Full Text] [Related]

  • 6. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
    Habu Y, Fukui Y, Maruno T, Hisatsune H, Kawai K.
    Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
    [Abstract] [Full Text] [Related]

  • 7. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP, Schenk E, Tan G, Snel P, Nelis F.
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [Abstract] [Full Text] [Related]

  • 8. [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y, Yoshino T, Shio S, Hayakumo T, Kawai K.
    Nihon Rinsho; 2004 Aug; 62(8):1504-9. PubMed ID: 15344541
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM, Gerrity MS, Anderson T.
    Eff Clin Pract; 2001 Aug; 4(6):263-70. PubMed ID: 11769299
    [Abstract] [Full Text] [Related]

  • 11. Treatment of gastroesophageal reflux disease: to step or not to step.
    McGuigan JE.
    Am J Gastroenterol; 2001 Jun; 96(6):1679-81. PubMed ID: 11419813
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
    Dean BB, Siddique RM, Yamashita BD, Bhattacharjya AS, Ofman JJ.
    Am J Health Syst Pharm; 2001 Jul 15; 58(14):1338-46. PubMed ID: 11471482
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Omeprazole is more cost-effective than ranitidine in reflux esophagitis].
    Lindberg G, Jönsson B.
    Lakartidningen; 1992 Jul 22; 89(30-31):2530-3. PubMed ID: 1507987
    [No Abstract] [Full Text] [Related]

  • 15. What is the best pharmacologic approach to managing moderate to severe heartburn?
    Melton ST, Cimmino A.
    J Fam Pract; 2001 Oct 22; 50(10):839. PubMed ID: 11674880
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
    Belousov IuB, Karpov OI, Belousov DIu, Beketov AS.
    Ter Arkh; 2007 Oct 22; 79(2):58-66. PubMed ID: 17460971
    [No Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
    Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G.
    Am J Gastroenterol; 2000 Feb 22; 95(2):395-407. PubMed ID: 10685741
    [Abstract] [Full Text] [Related]

  • 18. Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.
    Romagnuolo J, Meier MA, Sadowski DC.
    Ann Surg; 2002 Aug 22; 236(2):191-202. PubMed ID: 12170024
    [Abstract] [Full Text] [Related]

  • 19. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
    Harris RA, Kuppermann M, Richter JE.
    Am J Med; 1997 Jan 22; 102(1):78-88. PubMed ID: 9209204
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.
    Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA.
    Arch Fam Med; 2000 Jul 22; 9(7):624-30. PubMed ID: 10910310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.